Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from July 15, 2026

Partial Published before the outcome was known, scored automatically when the window closed on October 13, 2026 — -22.7% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted
$49.24 Published $52.50 Target $38.06 Window close $51.46 Peak
$45.82 – $48.75Entry zone — fair-value band
$49.24Published — price the day we called it
$52.50Target — the price the thesis aimed for
$51.46Peak — highest point inside the window, not a realized return
$38.06Window close — end-of-window price, context only

What happened

Partial

Reached 56% of the predicted growth at its peak, without hitting the target.

At window close
-22.7%
realized, from the publication price to the last close inside the window
Peak gain
+4.5%
peak, from the publication price — not a realized return
S&P 500, same window
+3.3%
SPY over the identical days, dividend-adjusted
Window close
$38.06
last close inside the window, ended October 13, 2026
Peak price
$51.46
peak on July 29, 2026 — not a realized return
Days to target
—

The thesis — published July 15, 2026

Predicted growth
+8%
over the measurement window
Target price
$52.50
the price the thesis aimed for
Entry zone
$45.82 – $48.75
the fair-value band we waited for
Price at publication
$49.24
published July 15, 2026
Confidence
72%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Novo Nordisk makes high-profit medicines for obesity and diabetes and is seeing very strong demand for Wegovy, which looks early-market leading in oral obesity. This combination makes growth fairly cheap right now. Still, the official price target is below the current price, debt is notable, and rivals, payers, or supply problems could slow a short-term recovery.

Primary drivers

  • Wegovy is ahead early in prescriptions for oral obesity
  • Strong, high-profit drugs for obesity and diabetes
  • Stock is less volatile and valuation offers backing
  • Risks from rivals, payer pressure, and elevated debt

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals